QQQ   386.20 (+0.80%)
AAPL   165.32 (+2.15%)
MSFT   326.19 (+0.98%)
FB   317.87 (+3.59%)
GOOGL   2,863.10 (+0.81%)
AMZN   3,427.37 (+1.11%)
TSLA   1,009.01 (-0.59%)
NVDA   300.37 (-2.14%)
BABA   123.60 (+10.40%)
NIO   32.34 (+0.59%)
CGC   10.15 (+1.60%)
AMD   139.06 (-3.44%)
GE   96.01 (+3.49%)
MU   82.45 (+1.02%)
T   23.28 (-0.77%)
F   19.22 (+0.42%)
DIS   150.37 (+2.84%)
PFE   51.48 (-5.14%)
AMC   28.79 (-0.76%)
ACB   5.97 (+2.58%)
BA   205.88 (+3.72%)
QQQ   386.20 (+0.80%)
AAPL   165.32 (+2.15%)
MSFT   326.19 (+0.98%)
FB   317.87 (+3.59%)
GOOGL   2,863.10 (+0.81%)
AMZN   3,427.37 (+1.11%)
TSLA   1,009.01 (-0.59%)
NVDA   300.37 (-2.14%)
BABA   123.60 (+10.40%)
NIO   32.34 (+0.59%)
CGC   10.15 (+1.60%)
AMD   139.06 (-3.44%)
GE   96.01 (+3.49%)
MU   82.45 (+1.02%)
T   23.28 (-0.77%)
F   19.22 (+0.42%)
DIS   150.37 (+2.84%)
PFE   51.48 (-5.14%)
AMC   28.79 (-0.76%)
ACB   5.97 (+2.58%)
BA   205.88 (+3.72%)
QQQ   386.20 (+0.80%)
AAPL   165.32 (+2.15%)
MSFT   326.19 (+0.98%)
FB   317.87 (+3.59%)
GOOGL   2,863.10 (+0.81%)
AMZN   3,427.37 (+1.11%)
TSLA   1,009.01 (-0.59%)
NVDA   300.37 (-2.14%)
BABA   123.60 (+10.40%)
NIO   32.34 (+0.59%)
CGC   10.15 (+1.60%)
AMD   139.06 (-3.44%)
GE   96.01 (+3.49%)
MU   82.45 (+1.02%)
T   23.28 (-0.77%)
F   19.22 (+0.42%)
DIS   150.37 (+2.84%)
PFE   51.48 (-5.14%)
AMC   28.79 (-0.76%)
ACB   5.97 (+2.58%)
BA   205.88 (+3.72%)
QQQ   386.20 (+0.80%)
AAPL   165.32 (+2.15%)
MSFT   326.19 (+0.98%)
FB   317.87 (+3.59%)
GOOGL   2,863.10 (+0.81%)
AMZN   3,427.37 (+1.11%)
TSLA   1,009.01 (-0.59%)
NVDA   300.37 (-2.14%)
BABA   123.60 (+10.40%)
NIO   32.34 (+0.59%)
CGC   10.15 (+1.60%)
AMD   139.06 (-3.44%)
GE   96.01 (+3.49%)
MU   82.45 (+1.02%)
T   23.28 (-0.77%)
F   19.22 (+0.42%)
DIS   150.37 (+2.84%)
PFE   51.48 (-5.14%)
AMC   28.79 (-0.76%)
ACB   5.97 (+2.58%)
BA   205.88 (+3.72%)
NYSE:RCUS

Arcus Biosciences Stock Forecast, Price & News

$43.83
-0.37 (-0.84%)
(As of 12/6/2021 12:00 AM ET)
Add
Compare
Today's Range
$43.42
$45.21
50-Day Range
$31.38
$48.47
52-Week Range
$22.36
$49.10
Volume
643,535 shs
Average Volume
579,846 shs
Market Capitalization
$3.08 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.88
30 days | 90 days | 365 days | Advanced Chart
Receive RCUS News and Ratings via Email

Sign-up to receive the latest news and ratings for Arcus Biosciences and its competitors with MarketBeat's FREE daily newsletter.


Arcus Biosciences logo

About Arcus Biosciences

Arcus Biosciences, Inc. engages in the development and commercialization of immunotherapies. It competes in the segments of the pharmaceutical, biotechnology and other related markets that develop immunotherapies for the treatment of cancer. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and is headquartered in Hayward, CA.

Headlines

Gilead (GILD) Exercises Options to Three Arcus Programs
November 19, 2021 |  finance.yahoo.com
Wedbush Boosts Arcus Biosciences (NYSE:RCUS) Price Target to $67.00
November 19, 2021 |  americanbankingnews.com
Arcus Biosciences (NYSE:RCUS) PT Raised to $100.00 at SVB Leerink
November 18, 2021 |  americanbankingnews.com
Why Arcus Biosciences Stock Is On Fire Today
November 18, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Fax
N/A
Employees
236
Year Founded
N/A

Sales & Book Value

Annual Sales
$77.52 million
Book Value
$7.72 per share

Profitability

Net Income
$-122.86 million
Net Margins
-735.12%
Pretax Margin
-735.12%

Debt

Price-To-Earnings

Miscellaneous

Free Float
56,403,000
Market Cap
$3.08 billion
Optionable
Optionable

Company Calendar

Last Earnings
11/08/2021
Today
12/06/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
2/23/2022

MarketRank

Overall MarketRank

2.40 out of 5 stars

Medical Sector

188th out of 1,390 stocks

Pharmaceutical Preparations Industry

77th out of 673 stocks

Analyst Opinion: 4.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -












Arcus Biosciences (NYSE:RCUS) Frequently Asked Questions

Is Arcus Biosciences a buy right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arcus Biosciences in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Arcus Biosciences stock.
View analyst ratings for Arcus Biosciences
or view top-rated stocks.

How has Arcus Biosciences' stock price been impacted by Coronavirus?

Arcus Biosciences' stock was trading at $16.97 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, RCUS shares have increased by 158.3% and is now trading at $43.83.
View which stocks have been most impacted by COVID-19
.

When is Arcus Biosciences' next earnings date?

Arcus Biosciences is scheduled to release its next quarterly earnings announcement on Wednesday, February 23rd 2022.
View our earnings forecast for Arcus Biosciences
.

How were Arcus Biosciences' earnings last quarter?

Arcus Biosciences, Inc. (NYSE:RCUS) announced its quarterly earnings results on Monday, November, 8th. The company reported ($1.11) earnings per share for the quarter, topping analysts' consensus estimates of ($1.13) by $0.02. The company earned $9.46 million during the quarter, compared to the consensus estimate of $9.27 million. Arcus Biosciences had a negative trailing twelve-month return on equity of 48.12% and a negative net margin of 735.12%. During the same quarter in the prior year, the business posted $0.03 EPS.
View Arcus Biosciences' earnings history
.

What price target have analysts set for RCUS?

7 Wall Street analysts have issued 1-year price targets for Arcus Biosciences' shares. Their forecasts range from $51.00 to $100.00. On average, they anticipate Arcus Biosciences' stock price to reach $64.25 in the next twelve months. This suggests a possible upside of 46.6% from the stock's current price.
View analysts' price targets for Arcus Biosciences
or view top-rated stocks among Wall Street analysts.

Who are Arcus Biosciences' key executives?

Arcus Biosciences' management team includes the following people:
  • Terry J. Rosen, Chairman & Chief Executive Officer
  • Juan Carlos Jaen, President & Director
  • Jennifer Jarrett, Chief Operating Officer & Director
  • Robert C. Goeltz, Chief Financial & Accounting Officer
  • Steve Young, Senior VP-Technology & Quantitative Biology

What is Terry Rosen, Ph.D.'s approval rating as Arcus Biosciences' CEO?

4 employees have rated Arcus Biosciences CEO Terry Rosen, Ph.D. on Glassdoor.com. Terry Rosen, Ph.D. has an approval rating of 100% among Arcus Biosciences' employees. This puts Terry Rosen, Ph.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Arcus Biosciences own?

When did Arcus Biosciences IPO?

(RCUS) raised $99 million in an initial public offering on Thursday, March 15th 2018. The company issued 7,100,000 shares at $13.00-$15.00 per share. Citigroup, Goldman Sachs and Leerink Partners served as the underwriters for the IPO.

What is Arcus Biosciences' stock symbol?

Arcus Biosciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "RCUS."

Who are Arcus Biosciences' major shareholders?

Arcus Biosciences' stock is owned by many different retail and institutional investors. Top institutional investors include EcoR1 Capital LLC (7.29%), BlackRock Inc. (5.89%), BVF Inc. IL (4.60%), Franklin Resources Inc. (2.07%), Geode Capital Management LLC (1.10%) and Sectoral Asset Management Inc (1.05%). Company insiders that own Arcus Biosciences stock include Carolyn C Tang, Gilead Sciences Inc, Jennifer Jarrett, Juan C Jaen, Kathryn E Falberg, Robert C Goeltz II, Terry J Rosen, William Grossman and Yasunori Kaneko.
View institutional ownership trends for Arcus Biosciences
.

Which major investors are selling Arcus Biosciences stock?

RCUS stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Morgan Stanley, Two Sigma Advisers LP, Two Sigma Investments LP, Victory Capital Management Inc., TimesSquare Capital Management LLC, Citadel Advisors LLC, and Deutsche Bank AG. Company insiders that have sold Arcus Biosciences company stock in the last year include Carolyn C Tang, Jennifer Jarrett, Juan C Jaen, Terry J Rosen, and William Grossman.
View insider buying and selling activity for Arcus Biosciences
or view top insider-selling stocks.

Which major investors are buying Arcus Biosciences stock?

RCUS stock was purchased by a variety of institutional investors in the last quarter, including EcoR1 Capital LLC, Franklin Resources Inc., Bain Capital Public Equity Management II LLC, BVF Inc. IL, BlackRock Inc., Granahan Investment Management Inc. MA, Sectoral Asset Management Inc, and Barclays PLC. Company insiders that have bought Arcus Biosciences stock in the last two years include Gilead Sciences Inc, Kathryn E Falberg, Robert C Goeltz II, William Grossman, and Yasunori Kaneko.
View insider buying and selling activity for Arcus Biosciences
or or view top insider-buying stocks.

How do I buy shares of Arcus Biosciences?

Shares of RCUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Arcus Biosciences' stock price today?

One share of RCUS stock can currently be purchased for approximately $43.83.

How much money does Arcus Biosciences make?

Arcus Biosciences has a market capitalization of $3.08 billion and generates $77.52 million in revenue each year. The company earns $-122.86 million in net income (profit) each year or ($4.10) on an earnings per share basis.

How many employees does Arcus Biosciences have?

Arcus Biosciences employs 236 workers across the globe.

What is Arcus Biosciences' official website?

The official website for Arcus Biosciences is www.arcusbio.com.

Where are Arcus Biosciences' headquarters?

Arcus Biosciences is headquartered at 3928 Point Eden Way, Hayward CA, 94545.

How can I contact Arcus Biosciences?

Arcus Biosciences' mailing address is 3928 Point Eden Way, Hayward CA, 94545. The company can be reached via phone at (510) 694-6200 or via email at [email protected].


This page was last updated on 12/6/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.